LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Search

Baxter International Inc

Suletud

SektorTervishoid

17.45 -1.41

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.4

Max

17.84

Põhinäitajad

By Trading Economics

Sissetulek

-137M

-15M

Müük

25M

2.8B

P/E

Sektori keskmine

86.308

106.172

Aktsiakasum

0.69

Dividenditootlus

3.68

Kasumimarginaal

-0.529

Töötajad

38,000

EBITDA

-46M

416M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+33.8% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.68%

2.31%

Järgmine dividendimakse kuupäev

2. jaan 2026

Järgmine aktsia dividendi kuupäev (ex-date)

28. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-2.8B

9.1B

Eelmine avamishind

18.86

Eelmine sulgemishind

17.45

Uudiste sentiment

By Acuity

50%

50%

182 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Baxter International Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. nov 2025, 23:07 UTC

Market Talk

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20. nov 2025, 22:22 UTC

Market Talk

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20. nov 2025, 22:08 UTC

Market Talk

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20. nov 2025, 21:57 UTC

Tulu

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20. nov 2025, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

20. nov 2025, 21:31 UTC

Tulu

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20. nov 2025, 21:23 UTC

Tulu
Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. nov 2025, 21:07 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q Rev $156.9M >BULL

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q EPS 7c >BULL

20. nov 2025, 21:05 UTC

Tulu

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20. nov 2025, 21:04 UTC

Tulu

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Consumer Rev $894M

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Guidance

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Global Business Solutions Rev $3B

Võrdlus sarnastega

Hinnamuutus

Baxter International Inc Prognoos

Hinnasiht

By TipRanks

33.8% tõus

12 kuu keskmine prognoos

Keskmine 23.67 USD  33.8%

Kõrge 36 USD

Madal 19 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Baxter International Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

10 ratings

2

Osta

7

Hoia

1

Müü

Tehniline skoor

By Trading Central

30.475 / 31.345Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

182 / 374 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
help-icon Live chat